The following is a list of abbreviations. For a complete list
of clinical trial terms, please click
here.
AAUCMB
average area under the curve minus baseline
ABS
abacavir
ACR 20
american college of rheumatology 20% responder rate
ADE
AIDS-defining event
ADR
adverse drug reaction
AE
adverse event
Ae
amount excreted in urine
Aet
cumulative urinary excretion from administration until time t
AIDS
acquired immunodeficiency deficiency syndrome
ALT
al anine aminotransferase
ANC
absolute neutrophil count
ANCOVA
analysis of covariance
ANOVA
analysis of variances
anti-HAT
humanized anti-Tac
anti-TNF
anti-tumor necrosis factor
anti-TNFα
anti-tumor necrosis factor-alpha
APV
Amprenavir
ARA
american rheumatism association
ARV
antiretroviral
AUC
area under the curve
AUC0-∞
area under the curve time 0-time infinity
AUCinf
area under the curve time infinity
AUCMB
area under the curve minus baseline
bid
bis in die (twice daily)
BL
baseline
BLQ
below limit of quantification
CA
competent authority
CCRC
certified clinical research coordinator
CI
confidence interval
CL/F
apparent clearance
CLdtot
total distribution clearance
CLiv
clearance after iv administration
CLpo
oral clearance
CLR
renal clearance
Cmax
maximum plasma concentration
Cmin
minimum plasma concentration
CMV
cytomegalovirus retinitis
CMVR
cytomegalovirus retinitis
CRA
clinical research associate
CRC
clinical research coordinator
CrCL
creatinine clearance
CRF
case report form
CRO
contract research organization
CRP
C-reactive protein
Css
plasma concentration at steady state
Cthrough
through plasma concentration
CTx
C-teleopeptide
d
day
D+
cytomegalovirus-seropositive donor
DAR
drug or device accountability records
dL
deciliter
DMARD
Disease-Modifying Anti-Rheumatic Drug
DT
diphtheria/tetanus
ECG/EKG
electrocardiogram
EFV
Efavirenz
EMEA
european medicines agency
EORTC
european organization for research and treatment of cancer
ESR
erythrocyte sedimentation rate
F
bioavailability
FDA
food and drug administration
FSGS
focal segmental glomerulosclerosis
g
gram
GC-MS
gas chromatograph mass spectrometer
GCP
good clinical practice
GGT
gamma-glutamyl transferase
HAART
highly active antiretroviral therapy
HAQ
health assessment questionnaire
HIV
human immunodeficiency virus
hr
hour
IEC
independent ethics committee
IND
investigational new drug application
IRB
institutional review board
ISR
injection site reaction
ITT
intention to treat
iv
intravenous
Kel
elimination constant
kg
kilogram
LC/MS/MS methods
liquid chromatography mass spectrometery
LOCF
last observation carried forward
LSM
least squares mean
m
meter
mcg
microgram
mg
milligram
MITT
modified intention to treat
mL
millilitre
mm
millimetre
mmol
millimole
MOS
medical outcomes study
MPA
mycophenolic acid
MPAG
mycophenolic acid glucuronide
MTX
methotrexate
NAG
N-acetyl-β-D-glucosaminidase
NDA
new drug application
ng
nanogram
OB
optimised background
OHRP
office for human research protection
OTC
over-the-counter
PD
phamacodynamics
PI
protease inhibitor
PK
pharmacokinetic
PNBC
periods with new bone complications
po
per os (oral)
pts-yrs
patient-years
PWFU
patients who withdrew from study prematurely
q12h
every 12 hours
QLQ-C30
quality of life questionnaire-core 30
QOL
quality of life
qow
every other week
R-
cytomegalovirus-seronegative
RA
rheumatoid arthritis
RNA
ribonucleic acid
RT
restricted treated
RTV
Ritonavir
SAE
serious adverse event
sc
subcutaneous
SD
standard deviation
SEM
standard error of the mean
SF-36
Short-Form 36
SMPR
skeletal morbidity period rate
SOP
standard operating procedure
SOT
solid organ transplant
t1/2p
bioloogical half-life of parent compound
t1/2u
urinary half-life
TBW
total body weight
tid
thrice daily
Tmax
time to maximum plasma concentration
TT
tetanus toxoid
V1
central (vascular) compartment
V2
peripheral (extra-vascular) compartment
Vss
volume of distribution at steady state
WHO
World Health Organization
WHO PS
World Health Organization performance status
yr
year
